Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14193352 | 1.00 | CPB1 (0.45) | CPB1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL4820567 | 1.00 | CPB1 (0.45) | CPB1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL11477364 | 0.83 | CPB1 (0.46) | CPB1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL11476182 | 0.83 | CPB1 (0.46) | CPB1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL11476185 | 0.83 | CPB1 (0.46) | CPB1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL11477360 | 0.83 | CPB1 (0.46) | CPB1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL26015243 | 0.79 | CPB1 (0.46) | CPB1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL4822281 | 0.78 | TSHR (0.54) | ALDH1A1TSHR | |
| SCHEMBL14193348 | 0.78 | TSHR (0.54) | ALDH1A1TSHR | |
| SCHEMBL24233326 | 0.77 | CA1 (0.52) | CPB1ALDH1A1GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365061-B2 | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2006055463-A2 | 2-AMINO-3-FUNCTIONALIZED TETRALIN DERIVATIVES AND RELATED GLYCOGEN PHOSPHORYLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | PYGM, PON1, GYS1 | CPB1 581/4885ALDH1A1 1037/4885GAA 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.